The real promise of improving patient outcomes in IgD and IgE multiple myeloma lies in multi-drug combinations, next-generation agents, and immunotherapy.
Claudia Paba-prada, MD
Advertisement
Articles by Claudia Paba-prada, MD
Advertisement
Latest Updated Articles
- IgD and IgE Variants of Myeloma: Valuable Insights and Therapeutic Opportunities
Published: August 15th 2013 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy
2
Early Detection, Education Are Key to Combat Rising Pancreatic Cancer Cases
3
Examining Developments in Safe Administration of Nuclear Agents
4
Sonrotoclax Earns FDA Priority Review in R/R Mantle Cell Lymphoma
5
